NeuroScientific’s StemSmart Therapy Delivers Strong Results in Fistulising Crohn’s Patients

Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ) has shared an announcement.

NeuroScientific Biopharmaceuticals reported that three of four patients with fistulising Crohn’s disease treated with its patented StemSmart™ mesenchymal stem cell therapy under Australia’s Special Access Scheme achieved a successful clinical response, while the fourth patient showed a partial response with ongoing assessment. The strong outcomes in this hard-to-treat patient group are being used to shape the design of later-phase clinical trials expected to begin in the second half of 2026, underpin Phase 2 start-up activities including commercial manufacturing and regulatory planning, and support the company’s strategy to establish a foothold in the multibillion-dollar global Crohn’s disease market while expanding StemSmart™ as a broader platform therapy for chronic inflammatory indications.

The most recent analyst rating on (AU:NSB) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Neuroscientific Biopharmaceuticals Ltd. stock, see the AU:NSB Stock Forecast page.

More about Neuroscientific Biopharmaceuticals Ltd.

NeuroScientific Biopharmaceuticals Limited (ASX:NSB) is an Australian biotechnology company developing novel mesenchymal stem cell-based therapies targeting immune-mediated inflammatory diseases, with a particular focus on Crohn’s disease and other chronic inflammatory conditions. Its lead platform, StemSmart™, is derived from adult human bone marrow-sourced MSCs and is positioned as a cell therapy with potential applications in areas of high unmet need, including fistulising Crohn’s disease, organ transplant immune tolerance, lung inflammatory disease and graft-versus-host disease.

Average Trading Volume: 220,567

Technical Sentiment Signal: Buy

Current Market Cap: A$38.25M

Learn more about NSB stock on TipRanks’ Stock Analysis page.